Legislative news on biosimilars, safety warning on epidural corticosteroid injections, and other drug updates rheumatologists need to know
Why Tweaking Molecular Structures Can Be Hazardous to Our Health
The rise and fall of rofecoxib and valdecoxib demonstrate the need for caution in new drug development
Rheumatology Drug Updates, Trials, Safety Data
Information on oral anticoagulant apixaban, apremilast for active psoriatic arthritis, hyaluronic acid and methotrexate injections, and drug safety updates rheumatologists need to know
Rheuminations: Ankylosing Spondylitis Sometimes Defies Detection
How method of diagnosing, treating this inflammatory back disease characterized by stiffness and the presence of HLA-B27 gene has evolved
Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis
New research clarifies terminology used for diagnosis, but questions remain around epidemiology, genetics and management of patients with axial skeletal inflammation
Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
Drug’s antiinflammatory properties may help alleviate pain in patients with OA, reduce risk of myocardial infarction, but toxicity, drug interactions need to be considered
Treatment Options, Guidelines for Managing Gout Discussed at the ACR/ARHP Winter Rheumatology Symposium
Better understanding of goals, effect of gout therapy with nonsteroidal anti-inflammatory drugs, urate lowering medication needed to improve quality of care
Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
Therapy with tumor necrosis factor inhibitors, nonsteroidal antiinflammatory drugs, ustekinumab in early stages of osteitis may halt molecular switching to bone-forming phenotype characteristic of SpA
Methotrexate May Mitigate Inflammatory Bone Disease Note Experts at the ACR/ARHP Winter Rheumatology Symposium
By regulating molecules key to osteoclast/osteoblast processes, methotrexate may reduce bone destruction in inflammatory arthritis, osteolysis, especially in combination with adenosine
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know